Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MoonLake Initiates Phase 3 VELA Program of sonelokimab for Hidradenitis Suppurativa
Details : M1095 (sonelokimab) is an investigational humanised Nanobody® targeting IL-17A and IL-17F, it is being evaluated for the treatment of moderate to severe hidradenitis suppurativa.
Product Name : M1095
Product Type : Antibody
Upfront Cash : Inapplicable
May 16, 2024
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RelabotulinumtoxinA
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Galderma’s Phase 3 Results Show Efficacy and Long Duration for Frown Lines and Crow's Feet
Details : QM1114-DP (relabotulinumtoxinA) is a botulinum toxin neuromodulator, which is under phase 3 clinical development for the treatment of glabellar frown lines & lateral canthal lines.
Product Name : Relfydess
Product Type : Protein
Upfront Cash : Inapplicable
January 16, 2024
Lead Product(s) : RelabotulinumtoxinA
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RelabotulinumtoxinA
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : QM1114-DP (RelabotulinumtoxinA) is a rapid and long lasting small molecule injection formulation, which is being investigated for dermatological conditions like Crow’s Feet and Frown Lines.
Product Name : Relfydess
Product Type : Protein
Upfront Cash : Inapplicable
November 30, 2023
Lead Product(s) : RelabotulinumtoxinA
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Samsung Bioepis
Deal Size : Undisclosed
Deal Type : Agreement
Samsung Bioepis Partners with Sandoz to Commercialize Ustekinumab Biosimilar Candidate
Details : Under the agreement, Sandoz will support Samsung Bioepis pipeline expansion by commercialising SB17, a proposed biosimilar to Stelara (ustekinumab) strengthening its immunology portfolio in the US, Canada, European Economic Area, Switzerland and UK.
Product Name : SB17
Product Type : Antibody
Upfront Cash : Undisclosed
November 09, 2023
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Samsung Bioepis
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Secukinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Novartis Cosentyx® Gains Positive CHMP Opinion for Hidradenitis Suppurativa
Details : Cosentyx (secukinumab) is the USFDA approved, human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis.
Product Name : Cosentyx
Product Type : Antibody
Upfront Cash : Inapplicable
April 26, 2023
Lead Product(s) : Secukinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Demerger
Details : Through the spinoff, Novartis will complete its transformation to become a leading, focused medicines company and Sandoz will work on its generic and biosimilars pipeline, including SB17 a proposed biosimilar to Stelara (ustekinumab).
Product Name : SB17
Product Type : Antibody
Upfront Cash : Undisclosed
April 10, 2023
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Demerger
Lead Product(s) : Secukinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cosentyx (secukinumab) is the human biologic that directly inhibits interleukin-17A, an important cytokine involved in the inflammation of psoriatic arthritis, moderate to severe plaque psoriasis, ankylosing spondylitis and non-radiographic axial spondyl...
Product Name : Cosentyx
Product Type : Antibody
Upfront Cash : Inapplicable
April 02, 2023
Lead Product(s) : Secukinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Demerger
Details : Through the divestment, Novartis will complete its transformation to become a leading, focused medicines company and Sandoz will work on its generic and biosimilars pipeline, including SB17 a proposed biosimilar to Stelara (ustekinumab).
Product Name : SB17
Product Type : Antibody
Upfront Cash : Undisclosed
March 10, 2023
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Demerger
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BotulinumtoxinA (RelabotulinumtoxinA) is designed as a liquid, avoiding the traditional requirement to reconstitute from powder, eliminating variability, errors and risks associated with reconstitution, which would be expected to improve the consistency ...
Product Name : Alluzience
Product Type : Protein
Upfront Cash : Inapplicable
October 06, 2022
Lead Product(s) : Botulinum Toxin A
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Secukinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and symptoms.
Product Name : Cosentyx
Product Type : Antibody
Upfront Cash : Inapplicable
September 09, 2022
Lead Product(s) : Secukinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable